PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao.

Dr. Koo is Professor of Clinical Dermatology at the University of California at San Francisco (UCSF) School of Medicine and Vice Chairman in the Department of Dermatology at the UCSF Medical Center. Active in clinical research, he is co-editor of Psoriasis Forum and an advisory board member of the Inflammatory Disease Institute, and serves on the editorial boards of Journal of American Academy of Dermatology, Dermatology Psychometrics, and Journal of Symptom Validity.

Dr. Liao is Assistant Professor of Dermatology at the University of California, San Francisco (UCSF). His main research interest is the genetics of psoriasis and psoriatic arthritis.

This seminar will review clinical protocols used to successfully employ the genetic test in dermatology practices. A review of the clinical studies supporting the test will be discussed. Participants are asked to register by Monday, November 30 via e-mail: ([email protected]) or calling 1-877-344-5445. Space is limited.

The PsoriasisDX Genetic Test helps identify those at high risk for developing psoriatic arthritis (PsA) before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.

“For dermatologists, this is an important educational seminar in the genetics of psoriasis and psoriatic arthritis,” says PsoriasisDX CEO Andy Goren. “PsoriasisDX is proud to sponsor this symposium as a global innovator in molecular dermatology.”

Source: PsoriasisDX

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New Recommendation Statement for BRCA1/2 evaluation still fails to address many problems